Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05913908 · ClinicalTrials.gov registry record · NA
EFS of the DUO System for Tricuspid Regurgitation
A NA study of Tricuspid Regurgitation and Heart Valve Diseases, sponsored by CroiValve Limited.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 16
- Study locations
NCT05913908: Recruiting NA study of Tricuspid Regurgitation and Heart Valve Diseases, sponsored by CroiValve Limited.
NCT05913908 is a NA study of Tricuspid Regurgitation and Heart Valve Diseases that is actively recruiting participants, run by CroiValve Limited. The registered enrollment target is 15 participants, below the 535-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (97% lower). The trial reports 16 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05913908, a NA study of Tricuspid Regurgitation and Heart Valve Diseases, is actively recruiting participants, sponsored by CroiValve Limited.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 16
- Study locations
Study Summary
The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).
Primary Outcome
* Death * Reintervention * Disabling stroke * Myocardial infarction * Major access site and vascular complications * Severe bleeding * Renal failure requiring dialysis * Major cardiac structural complications * Pulmonary embolism
Conditions Studied
Interventions
- DEVICE DUO Transcatheter Tricuspid Coaptation Valve System
Study Locations (16)
New York
- Columbia University Medical Center/NYPH - New York
- Montefiore Medical Center - The Bronx
Arizona
- Dignity Health St. Joseph's Hospital & Medical Center - Phoenix
California
- Los Robles Hospital & Medical Center - Thousand Oaks
Georgia
- Piedmont Heart Institute - Atlanta
Illinois
- Northwestern University - Chicago
Kansas
- Ascension Via Christi Research - Wichita
Minnesota
- Allina Health Minneapolis Heart Institute Foundation - Minneapolis
Ohio
- OhioHealth Research Institute - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2029-10 |
| Phase | NA |
What NCT05913908 shows while recruiting
NCT05913908 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 535-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Tricuspid Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which DUO Transcatheter Tricuspid Coaptation Valve System is the first listed.
NCT05913908 lists 16 locations in 15 states (New York, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT05913908 about?
NCT05913908 is a clinical study titled "EFS of the DUO System for Tricuspid Regurgitation". The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).
What is the current status of trial NCT05913908?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-08-13. Estimated completion is 2029-10.
What conditions does trial NCT05913908 study?
This clinical trial studies the following conditions: Tricuspid Regurgitation, Heart Valve Diseases, Tricuspid Valve Disease, Tricuspid Valve Insufficiency.
What interventions are being tested in trial NCT05913908?
The interventions under investigation include: DUO Transcatheter Tricuspid Coaptation Valve System (DEVICE).
Who is sponsoring clinical trial NCT05913908?
This trial is sponsored by CroiValve Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05913908 being conducted?
This trial has 16 study locations across Arizona, California, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tricuspid Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05913908's enrollment target sits among peer trials
15 17th of 17 the lowest of 17 other Tricuspid Regurgitation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tricuspid Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TTVR Early Feasibility Study
RECRUITING · NA
-
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
RECRUITING · NA
-
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
RECRUITING · NA
-
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
RECRUITING · NA
-
Trisol System EFS Study
RECRUITING · NA
-
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI